Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
No impact of increasing symptoms on quality of life? Longitudinal data from the German MALIFE-Project on patients receiving monochemo- and endocrine treatment for advanced breast cancer – results from the TMK registry group.

Marschner, N., Nusch, A., Decker, T., Münz, M., Kruggel, L., Jänicke, M., 2015.

The Breast 24 (suppl3) (OR51), 39. doi:10.1016/S0960-9776(15)30063-1

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: ABC3 / Journal: The Breast
TMK
2015
No impact of increasing symptom burden on quality of life? – Longitudinal data from the German MaLife-Project on patients receiving monochemo- and endocrine treatment for metastatic breast cancer.

Marschner, N., Nusch, A., Decker, T., Münz, M., Kruggel, L., Jänicke, M., 2015.

Oncol Res Treat 38 (suppl 5)(V670), 202. doi:10.1159/00043907

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TMK
2015
Survival data from patients with advanced or metastatic renal cell carcinoma in routine practice differs significantly from clinical trial data – Analyses from the German clinical RCC Registry.

Marschner, N., Müller, L., Staehler, M., Nusch, A., Münz, M., Koska, M., Jänicke, M., Goebell, P., 2015.

Oncol Res Treat 38 (suppl.5)(V674), 204. doi:10.1159/000439070

Abstract

Download

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TNK
2015
Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer – Results from a prospective cohort study.

Marschner, N., Arnold, D., Engel, E., Hutzschenreuter, U., Rauh, J., Freier, W., Hartmann, H., Frank, M., Jänicke, M., 2015.

Clinical Epidemiology 7, 295–303. doi:10.2147/CLEP.S73857

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: - / Journal: Journal of Clinical Epidemiology
TKK
2015
NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim – First Interim Analysis.

Kurbacher, C.M., Fietz, T., Diel, I.J., Egert, M., Hurtz, H.-J., Lück, A., Weide, R., Salat, C., Wolff, T., Zaiss, M., Klare, P., Losem, C., Illmer, T., Weißenborn, G., Steffens, C.-C., Schulze, M., Tesch, H., Oskay-Oezcelik, G., Teichmann, B., Harde, J., Scheuerlein, R.W., 2015.

Oncol Res Treat 38, 221–229. doi:10.1159/000381631

Abstract

Indikation: Supportive Therapy, Supportivtherapie / Veranstaltung: - / Journal: Oncology Research and Treatment
NADIR
2015
Prophylactic treatment of chemotherapy-induced neutropenia with Lipegfilgrastim in patients with breast cancer: subgroup analysis of the non-interventional study NADIR.

Kurbacher, C., Fietz, T., Salat, C., Zaiss, M., Gazawi, N., Steffens, C.-C., Egert, M., Graffunder, G., Papke, J., Weißenborn, G., Brückner, U., Illmer, T., Jungberg, P., Lorenz, A., Weide, R., Klare, P., Tesch, H., Oskay-Oezcelik, G., Teichmann, B., Harde, J., Scheuerlein, R., 2015.

Oncol Res Treat 38 (suppl.5)(P255), 77–78. doi:10.1159/000439070

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
NADIR
2015
Osteoprotektive Behandlung von Patientinnen mit ossär metastasiertem Mammakarzinom – Daten zur Behandlungsrealität aus dem Tumorregister Mammakarzinom.

Köhler, A., Tesch, H., Nusch, A., Fietz, T., Kruggel, L., Spring, L., Jänicke, M., Marschner, N., 2015.

Senologie – Zeitschrift für Mammadiagnostik und -therapie 12, A77 (02). doi:10.1055/s-0035-1550517

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: Senologie Kongress / Journal: Senologie
TMK
2015
Revlimid-NIS: Non-interventional study on therapy of relapsed/ refractory multiple myeloma with a combination of Lenalidomide plus Dexamethasone

Knauf, W., Aldaoud, A., Maintz, C., Groschek, M., Teichmann, B., Harde, J., Trarbach Tanja, 2015.

Oncol Res Treat 38 (suppl.5)(P783), 238. doi:10.1159/000439070

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
Revlimid-NIS
2015
1st-line treatment of patients with high-grade non-Hodgkin’s lymphoma: Similar effectiveness with R-CHOP-14 or R-CHOP-21 – Data from the German prospective TLN Registry.

Knauf, W., Abenhardt, W., Mohm, J., Rauh, J., Grugel, R., Harde, J., Jänicke, M., Marschner, N., 2015.

Oncol Res Treat 38 (suppl 5)(V75), 19. doi:10.1159/000439070

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TLN
2015
Progression-free and overall survival of patients with advanced or metastatic pancreatic cancer in German outpatient centers – first outcome data from the clinical TPK Registry.

Hegewisch-Becker, S., Hofheinz, R., Wolf, T., Aldaoud, A., Harde, J., Kopfmann, S., Marschner, N., 2015.

Oncol Res Treat 38 (suppl 5)(V26), 5. doi:10.1159/000439070

Abstract

Indikation: Pancreatic Cancer, Pankreaskarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TPK
2015